CALGARY, Alberta, May 15, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Maple Leaf Green World Inc. ("Maple Leaf" or the "Company") (((NEO: MGW, OTCQX:MGWFF) is pleased to announce that the Licensing and Medical Access Directorate, Controlled Substances and Cannabis Branch of Health Canada has completed a preliminary and high-level review of the Company's Standard Cultivation and Standard Processing licences application. Based on the information assessed, Health Canada has no critical concerns with the application at this time. This review was limited in scope and included a verification of the licence class or subclass applied for, site address, and corporate structure. Health Canada is now requesting the Company to submit evidence to demonstrate that the fully built site of its Telkwa, British Columbia, Facility ("the Facility") meets all the requirements of the Cannabis Regulations.

Maple Leaf is a public Canadian company that focuses on the cannabis industry in North America. The Company currently has cannabis projects in British Columbia and California. With over 10 years of extensive greenhouse management experience, the Company applies its eco-agriculture knowledge and cultivation technology to produce contaminant-free cannabis products. Maple Leaf's long-term objective is to produce cannabis oil and to export its products to approved countries. The Company's common shares are listed for trading on the Aequitas NEO Exchange Inc. under the symbol "MGW" and on the OTCQX market under the symbol "MGWFF."

This news release may include forward-looking statements including opinions, assumptions, estimates, the Company's assessment of future plans and operations, and, more particularly, statements concerning: the receipt of a cultivation license from Health Canada and the timing thereof; the cultivation of cannabis at the Facility. When used in this document, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company that include, but are not limited to, the timely receipt of all required regulatory and third-party approvals, including cultivation and sales licenses from Health Canada. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to: regulatory and third party approvals, including receipt of cultivation and sales licenses from Health Canada, not being obtained in the manner or timing anticipated; the ability to implement corporate strategies; the state of domestic capital markets; the ability to obtain financing; changes in general market conditions; industry conditions and events; the size of the medical marijuana market and the recreational marijuana market; government regulations, including future legislative and regulatory developments involving medical and recreational marijuana; construction delays; risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks which can have a significant impact on the size and quality of the harvest of cannabis crops; competition from other industry participants; and other factors more fully described from time to time in the reports and filings made by the Company with securities regulatory authorities. Please refer to the Company's annual information form ("AIF") for the year ended December 31, 2018 and management's discussion and analysis ("MD&A") thereof for additional risk factors relating to the Company. The AIF and MD&A can be accessed under the Company's profile on www.sedar.com.